论文部分内容阅读
目的观察轻中度呼吸窘迫综合征早产儿应用氨溴索治疗的临床效果。方法取2012年7月~2013年4月本院收治60例新生儿肺透明膜病患儿并随机将其均分为对照组与实验组各30例,对照组接受经鼻持续气道正压通气(NCPAP)治疗,实验组在此基础上给予大剂量氨溴索治疗,观察两组住院天数、病情转归、呼吸指标及并发症情况。结果与对照组相比,实验组用氧时间更短、呼吸窘迫症状以及血气指标改善更明显、并发症发生率更低(P<0.05)。结论在新生儿轻中度呼吸窘迫综合征治疗中,应用大剂量氨溴索可收到满意疗效,临床应予以推广应用。
Objective To observe the clinical effect of ambroxol in premature infants with mild to moderate respiratory distress syndrome. Methods From July 2012 to April 2013, 60 neonates with hyaline membrane disease were admitted to our hospital and randomly divided into control group and experimental group, 30 cases in each group. The control group received nasal continuous positive airway pressure (NCPAP). The experimental group was given high-dose ambroxol on this basis. The days of hospitalization, the prognosis of the patients, the respiratory index and complication were observed. Results Compared with the control group, the oxygen consumption time of the experimental group was shorter, the symptoms of respiratory distress and blood gas index improved more obviously, and the complication rate was lower (P <0.05). Conclusion In the treatment of mild to moderate respiratory distress syndrome in neonates, the application of high-dose ambroxol can receive a satisfactory curative effect, which should be promoted and applied clinically.